Normal D-dimer levels after anticoagulation linked with reduced risk of thromboembolism | Fecal transplant treats Crohn's disease, ulcerative colitis in animal studies | Study finds hepatitis B antiviral drugs are not linked with renal risks
 
January 23, 2015
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top StorySponsored By
Normal D-dimer levels after anticoagulation linked with reduced risk of thromboembolism
Women who achieved normal D-dimer levels after anticoagulant treatment for a first venous thromboembolism were at lower risk for recurrence, according to a study in the Annals of Internal Medicine. The study of 410 patients found support for stopping anticoagulation therapy in women but not men based on D-dimer levels. Healio (free registration)/HemOnc Today (1/21)
Share: LinkedInTwitterFacebookGoogle+Email
Quotient releases Expanded RhD- Antibody Screen
Our new screen is the only one of its kind on the market. It has 3 RhD- cells carefully chosen to optimize homozygosity for full detection of unexpected alloantibodies beyond anti-D. A fourth RhD+ cell is included to confirm a passively or actively acquired anti-D. One-step process reduces the chance of human error. Call your Quotient Account Executive.
Advertisement
 
Science & Health
Fecal transplant treats Crohn's disease, ulcerative colitis in animal studies
University of Utah researchers have found that fecal transplants appear to reverse autoimmune diseases of the bowel such as Crohn's disease and ulcerative colitis in mice. The transplant of fecal material in mice via a tube into the stomach restored the balance of intestinal flora and normalized the intestines' function. The study appears in the journal Cell Host & Microbe. Voice of America (1/22)
Share: LinkedInTwitterFacebookGoogle+Email
Study finds hepatitis B antiviral drugs are not linked with renal risks
Hepatitis B patients receiving antiviral therapy may not have higher risks of renal disease, regardless of their pretreatment risks, according to research from Turkey. Researchers used the Modification of Diet in Renal Disease formula to monitor glomerular filtration rates for the 2,221 HBV patients in the study. Healio (free registration) (1/20)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends
Large Ebola vaccine trial to begin in Liberia
The National Institutes of Health announced that it will test two experimental Ebola vaccines from Merck & Co. and GlaxoSmithKline in Liberia in the coming weeks. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the new vaccines are being shipped and clinical sites are being prepared for the placebo-controlled trials, which will involve 27,000 people. The Hill (1/22), The Wall Street Journal (tiered subscription model) (1/23)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
Grant supports trial of MultiStem as treatment for respiratory distress syndrome
Athersys has received about $3 million from Innovate UK to begin a Phase IIa trial of MultiStem as a therapy for acute respiratory distress syndrome. The trial will be conducted with the nonprofit group Cell Therapy Catapult. Crain's Cleveland Business (1/22)
Share: LinkedInTwitterFacebookGoogle+Email
NIAID to fund additional early-stage trials of infectious disease treatments
The National Institute of Allergy and Infectious Diseases has added Duke University to the Phase 1 Clinical Trial Units for Therapeutics program, enabling up to a dozen more early-stage clinical trials each year. The other funded organizations are DynPort Vaccine and Clinical Research Management. Healio (free registration)/Infectious Disease News (1/18), OutSourcing-Pharma.com (1/21)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
Genzyme receives approval for eliglustat in Europe
The European Commission has granted marketing authorization for Genzyme's eliglustat, or Cerdelga, for the treatment of Gaucher disease. The approval was based on a 400-patient study that found the oral drug improved platelet and hemoglobin levels, spleen size and liver volume. PharmaTimes (U.K.) (1/22)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
AABB posts transcript from "Ask the FDA and CMS/CLIA" session
A transcript from the "Ask the FDA and CMS/CLIA" session that took place during the 2014 AABB Annual Meeting is now available online. Experts responded to questions about technical consultant qualifications under CLIA moderate/high complexity testing requirements, competency assessments and proficiency testing requirements. In addition, panelists addressed questions related to platelet dating and bacterial testing of platelets; clarification of syphilis results notification recommendations from the 2014 guidance; processing changes made by cord blood manufacturers that may require a supplement; current considerations for Hematopoietic Progenitor Cell Apheresis products; medical device data systems; laboratory-developed tests; and FDA plans for interventions to prevent transfusion transmission of the chikungunya, dengue and Ebola viruses.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
Director, Business DevelopmentThe Blood ConnectionGreenville, SC
Quality Compliance AuditorBlood Systems, Inc.Scottsdale, AZ
Customer Relations SpecialistIndiana Blood CenterIndianapolis, IN
Clinical Laboratory ScientistEisenhower Medical CenterRancho Mirage, CA
Click here to view more job listings.
 
SmartQuote
Rough diamonds may sometimes be mistaken for worthless pebbles."
-- Thomas Browne,
English author
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information